메뉴 건너뛰기




Volumn 13, Issue 10, 2013, Pages 1969-1978

Flow-based pipeline for systematic modulation and analysis of 3D tumor microenvironments

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FIBRONECTIN; LY 2157299; SB 525334; SJN 2511; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

EID: 84876931434     PISSN: 14730197     EISSN: 14730189     Source Type: Journal    
DOI: 10.1039/c3lc41300d     Document Type: Article
Times cited : (39)

References (51)
  • 45
    • 37549053307 scopus 로고    scopus 로고
    • Eli Lilly and Compan. A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US) 2000- [cited 2012]. Available from: NLM Identifier: NCT01220271
    • Y. Shintani M. Maeda N. Chaika K. R. Johnson M. J. Wheelock Am. J. Respir. Cell Mol. Biol. 2008 38 95 104
    • (2008) Am. J. Respir. Cell Mol. Biol. , vol.38 , pp. 95-104
    • Shintani, Y.1    Maeda, M.2    Chaika, N.3    Johnson, K.R.4    Wheelock, M.J.5
  • 46
    • 67349217954 scopus 로고    scopus 로고
    • Eli Lilly and Company. A Study of LY2157299 in Patients With Hepatocellular Carcinoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US) 2000- [cited 2012]. Available from: NLM Identifier: NCT01246986 Selleckchem: LY2157299 Biological Activity [Internet]. Boston (MA): Selleck Chemicals; c2011 [cited 2012]. Available from: http://www.selleckchem.com/products/ly2157299.html
    • E. Calvo-Aller J. Baselga S. Glatt A. Cleverly M. Lahn C. L. Arteaga M. L. Rothenberg M. A. Carducci J. Clin. Oncol. 2008 26 14554
    • (2008) J. Clin. Oncol. , vol.26 , pp. 14554
    • Calvo-Aller, E.1    Baselga, J.2    Glatt, S.3    Cleverly, A.4    Lahn, M.5    Arteaga, C.L.6    Rothenberg, M.L.7    Carducci, M.A.8


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.